Abstract
Burkitt lymphoma (BL) is the most common childhood cancer in sub‐Saharan Africa. Despite excellent outcomes in high‐income settings, the delivery of intensive multi‐agent chemo‐immunotherapy is prevented in low‐income countries by high costs and insufficient supportive care facilities. Consequently, patient outcome remains unsatisfactory and new therapeutic approaches are urgently needed to improve survival
Original language | English |
---|---|
Pages (from-to) | 51-51 |
Journal | British Journal of Haematology |
Volume | 182 |
Issue number | s1 |
DOIs | |
Publication status | Published - 19 Sept 2018 |
Event | Sixth International Symposium on Childhood, Adolescent and Young Adult Non-Hodgkin Lymphoma - Rotterdam, Netherlands Duration: 26 Sept 2018 → 29 Sept 2018 https://onlinelibrary.wiley.com/toc/13652141/2018/182/S1 |